Answers are grounded in this paper and cite their sources.
Neuromyelitis optica spectrum disorders are rare chronic autoimmune inflammatory demyelinating diseases of the central nervous system. Considering that the increase in neurological deficit in neuromyelitis optica spectrum disorders is mainly due to repeated exacerbations, the goals of pharmacotherapy are represented by the relief of relapses and the prevention of their development. Information about indications for therapy and side effects is necessary to identify the benefits and risks for patients with neuromyelitis optica spectrum disorders in each individual case.
No takes yet. Share an insight, caveat, or question.
Е. S. Novikova (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: